Last reviewed · How we verify
Anti SARS-CoV-2 equine hyperimmune serum
At a glance
| Generic name | Anti SARS-CoV-2 equine hyperimmune serum |
|---|---|
| Sponsor | Caja Costarricense de Seguro Social |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody F(ab')2 Fragments (INOSARS) for Adult Patients With Mild COVID-19 (PHASE1)
- Effectiveness and Safety Study of Specific Hyperimmune Equine Serum for the Treatment of Severe Hospitalized SARS-CoV-2 in Adults: Retrospective Cohort Study
- Safety and Effectiveness of an Immunobiological Drug in CoViD-19 (PHASE2, PHASE3)
- Efficacy and Safety of Three Different Doses of an Anti SARS-CoV-2 Hyperimmune Equine Serum in COVID-19 Patients (PHASE2, PHASE3)
- Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients (PHASE2)
- A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19. (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: